The TRAUM Project targets the development of pharmaceutical products with high impact in patients’ lives. This project is a repurposing strategy, based in a compound that already overcame phase I and II clinical trial phases, that confirmed a low toxicological profile and demonstrates substantial biological efficacy. Previous research was led by our CSO, Javier Dotor Ph.D, generating over 50 Proofs of Concept (PoC) in a wide range of clinical indications. TRAUM project combines previous research and the comprehensive knowledge of our CSO in the compound under development and the therapeutic molecular target, also guided by an outstanding Scientific Advisory Board. We are focus on the development of clinical products for new indications, primarily oncological, supported by available positive in vivo PoC, with notably clinical relevance due to the high homology between laboratory animals and humans molecular target and pathological mechanisms.
It is a unique company since it develops a comprehensive solution for the problems associated with breast cancer.
Our products in development, based on positive proofs of concept in animal models, achieve:
– Increased immune response of the patient, which is specified in a higher cure rate and significant reduction in the appearance of metastases.
– Reduction of damage to organs and deep tissue of the breast associated with radiotherapy.
– Reduction of superficial tissue damage (epidermis, dermis and nerve endings) associated with radiotherapy treatment and mastectomy surgical procedures.
Thanks to this comprehensive solution, action is taken both at the level of antitumor treatment and in the protection of internal organs (heart and lungs) and in the preservation of breast tissue, with a view to maintaining healthy tissue, subsequent breast reconstruction and maintenance of sensitivity breast erogenous.
Disit Biotech is particularly proud to collaborate with the Pink Knot Project, a global initiative that aims to impact in the universe of breast cancer.
Ph.D. CUM LAUDE
Molecular and Cellular Biology. University of Navarra.
LEADING INTERNATIONAL EXPERT IN THE ACTIVE COMPOUND AND THERAPEUTIC TARGET
Highest accumulated experience in the development of previous basic research on the active compound and remarkable expertise in the molecular target.
DISCOVERY AND DEVELOPMENT OF THE ACTIVE PHARMACEUTICAL INGREDIENT CLINICAL INDICATIONS
Transversal knowledge and approach to drug development pathway.
SCIENTIFIC PROJECT MANAGER
Wide experience in management and scientific direction.
AUTHOR IN 50 INTERNATIONAL SCIENTIFIC ARTICLES
Basic and applied research in the active compound and therapeutic target in different clinical indications.
Author in 9 international family patents Experience in intellectual property strategy
SUCCSESFULL TRACK RECORD IN PUBLIC FUNDS RAISING
EU programs 7PM, H2020 and National public fundings programs.
University of Navarra, ESAME, MICOM-UAM, Francisco de Vitoria University.
Scientific Advisoy Board
® DISITBIOTECH – 2021